GoAI
Get started
Novocure Ltd logo

Novocure Ltd

NVCR

NASDAQHealthcareMedical - Devices

Open in GoAI

Latest quote

$17.09

−$0.67 · -3.77%

Aug 21, 3:55 PM ET

NVCR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

76

Undervalued

Momentum

57

Neutral

Sentiment

65

Bullish

Risk resilience

53

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
CH
CEO
Frank Leonard
Listed since
Oct 2, 2015
Employees
1,605

Market position

Volume
1.4M
0.82× average
Average volume
1.71M
Average daily volume
Market cap
1.99B USD
Beta
0.98
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.63B USD
P/E (TTM)
-13.15×
P/B (TTM)
5.87×
P/S (TTM)
2.85×
EV / EBITDA
-13.67×
Earnings yield
-9.45%
Free cash flow yield
-5.25%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
76.13%
Operating margin
-22.08%
Net margin
-21.25%
Return on equity
-40.01%
Return on assets
-16.94%
Return on invested capital
-25.94%

Financial health

Debt / equity
0.69×
Current ratio
2.9×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends91%41%-8%-58%Gross margin, FY2021: 78.53%Gross margin, FY2022: 78.64%Gross margin, FY2023: 74.81%Gross margin, FY2024: 77.33%Gross margin, FY2025: 74.54%Operating margin, FY2021: -8.29%Operating margin, FY2022: -16.64%Operating margin, FY2023: -45.72%Operating margin, FY2024: -28.17%Operating margin, FY2025: -23.47%Net margin, FY2021: -10.91%Net margin, FY2022: -17.20%Net margin, FY2023: -40.65%Net margin, FY2024: -27.86%Net margin, FY2025: -20.79%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 78.53%. Gross margin FY2022 78.64%. Gross margin FY2023 74.81%. Gross margin FY2024 77.33%. Gross margin FY2025 74.54%. Operating margin FY2021 -8.29%. Operating margin FY2022 -16.64%. Operating margin FY2023 -45.72%. Operating margin FY2024 -28.17%. Operating margin FY2025 -23.47%. Net margin FY2021 -10.91%. Net margin FY2022 -17.20%. Net margin FY2023 -40.65%. Net margin FY2024 -27.86%. Net margin FY2025 -20.79%.

Income trends

Revenue

655.35M USD+8.28%

Operating income

−153.8M USD+9.79%

Net income

−136.23M USD+19.21%
Income trends across reported periods744.18M USD388.89M USD33.6M USD−321.69M USDRevenue, FY2021: 535.03M USDRevenue, FY2022: 537.84M USDRevenue, FY2023: 509.34M USDRevenue, FY2024: 605.22M USDRevenue, FY2025: 655.35M USDOperating income, FY2021: −44.33M USDOperating income, FY2022: −89.52M USDOperating income, FY2023: −232.87M USDOperating income, FY2024: −170.5M USDOperating income, FY2025: −153.8M USDNet income, FY2021: −58.35M USDNet income, FY2022: −92.53M USDNet income, FY2023: −207.04M USDNet income, FY2024: −168.63M USDNet income, FY2025: −136.23M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 535.03M USD. Revenue FY2022 537.84M USD. Revenue FY2023 509.34M USD. Revenue FY2024 605.22M USD. Revenue FY2025 655.35M USD. Operating income FY2021 −44.33M USD. Operating income FY2022 −89.52M USD. Operating income FY2023 −232.87M USD. Operating income FY2024 −170.5M USD. Operating income FY2025 −153.8M USD. Net income FY2021 −58.35M USD. Net income FY2022 −92.53M USD. Net income FY2023 −207.04M USD. Net income FY2024 −168.63M USD. Net income FY2025 −136.23M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue655.35M USD605.22M USD509.34M USD537.84M USD535.03M USD
Cost of goods sold166.88M USD137.18M USD128.28M USD114.87M USD114.88M USD
Gross profit488.47M USD468.04M USD381.06M USD422.97M USD420.15M USD
Research and development224.54M USD209.65M USD223.06M USD206.09M USD201.3M USD
Selling, general, and administrative417.73M USD428.89M USD390.87M USD306.41M USD263.18M USD
Operating expenses642.27M USD638.54M USD614.67M USD512.5M USD464.49M USD
Interest income18.11M USD51M USD46.04M USD15.79M USD1.1M USD
Interest expense—11.66M USD4.91M USD8.11M USD8.84M USD
Depreciation and amortization17.2M USD11.24M USD10.97M USD10.62M USD10.25M USD
Operating income−153.8M USD−170.5M USD−232.87M USD−89.52M USD−44.33M USD
Net income−136.23M USD−168.63M USD−207.04M USD−92.53M USD−58.35M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-1.22
FY2025
Latest fiscal-year revenue
655.35M USD
FY2025 · +8.28% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend-0.42-0.98-1.53-2.09FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend669.95M611.55M553.14M494.74MFY21FY22FY23FY24FY25

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$26.00

52.05% upside
Past 12 months12-month forecast

Price history unavailable

High $32.00Average $26.00Low $20.00

Rating distribution

15 ratings
Strong buy00%
Buy960%
Hold533%
Sell17%
Strong sell00%

Recent analyst actions

6 institutions

NVCR peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding NVCR

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
51.99M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
48.7M
Weight
0.06%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
37.57M
Weight
0.02%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
21.68M
Weight
0.05%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$358.65+0.70%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
17.99M
Weight
0.02%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
16.31M
Weight
0.11%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
13.86M
Weight
0.13%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
9M
Weight
0.04%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%

Continue in GoAI

Research NVCR

research.disclaimer